Browse by author
Lookup NU author(s): Dr Zakareya Gamie
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Introduction: Mesenchymal stem cells (MSCs) can be obtained from a wide variety of tissues for bone tissue engineering such as bone marrow, adipose, birth-associated, peripheral blood, periosteum, dental and muscle. MSCs from human fetal bone marrow and embryonic stem cells (ESCs) are also promising cell sources.Areas covered: In vitro, in vivo and clinical evidence was collected using MEDLINE (R) (1950 to January 2014), EMBASE (1980 to January 2014) and Google Scholar (1980 to January 2014) databases.Expert opinion: Enhanced results have been found when combining bone marrow-derived mesenchymal stem cells (BMMSCs) with recently developed scaffolds such as glass ceramics and starch-based polymeric scaffolds. Preclinical studies investigating adipose tissue-derived stem cells and umbilical cord tissue-derived stem cells suggest that they are likely to become promising alternatives. Stem cells derived from periosteum and dental tissues such as the periodontal ligament have an osteogenic potential similar to BMMSCs. Stem cells from human fetal bone marrow have demonstrated superior proliferation and osteogenic differentiation than perinatal and postnatal tissues. Despite ethical concerns and potential for teratoma formation, developments have also been made for the use of ESCs in terms of culture and ideal scaffold.
Author(s): Gamie Z, MacFarlane RJ, Tomkinson A, Moniakis A, Tran GT, Gamie Y, Mantalaris A, Tsiridis E
Publication type: Review
Publication status: Published
Journal: Expert Opinion on Biological Therapy
Year: 2014
Volume: 14
Issue: 11
Pages: 1611-1639
Print publication date: 01/11/2014
ISSN (print): 1471-2598
ISSN (electronic): 1744-7682
Publisher: INFORMA HEALTHCARE
URL: http://dx.doi.org/10.1517/14712598.2014.945414
DOI: 10.1517/14712598.2014.945414
